

ISSUE @ A GLANCE

-  **'The lower the better' revisited: low-density lipoprotein and lipoprotein(a)**
T.F. Lüscher 2509

CardioPulse

- Hugo A. Katus MD PhD FESC
J. Ozkan 2513
- CIT 2018: A New Era, New Journey
R. Gao 2515
- The ESC Publications Ethics Committee
M.L. Simoons, M. Daemen, K. Fox, D. Garcia-Dorada, C. Hamm, and U. Ravens 2518
- Hands-on training in acute cardiac care
K.A. Krychtiuk, R.M. Asenjo, and H. Bueno 2521
- Russian National Congress of Cardiology 2018 2525


CLINICAL REVIEW

Clinical update

-  **Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract**
F. Mach, K.K. Ray, O. Wiklund, A. Corsini, A.L. Catapano, E. Bruckert, G. De Backer, R.A. Hegele, G.K. Hovingh, T.A. Jacobson, R.M. Krauss, U. Laufs, L.A. Leiter, W. März, B.G. Nordestgaard, F.J. Raal, M. Roden, R.D. Santos, E.A. Stein, E.S. Stroes, P.D. Thompson, L. Tokgozlu, G.D. Vladutiu, B. Gencer, J.K. Stock, H.N. Ginsberg, and M.J. Chapman; European Atherosclerosis Society Consensus Panel 2526

CURRENT OPINION

Prevention and epidemiology



Lipids

-  **'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies**
L. Annemans, C.J. Packard, A. Briggs, and K.K. Ray 2546

CLINICAL RESEARCH

Lipids

- Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes**
D. Clark III, S.J. Nicholls, J.St. John, M.B. Elshazly, S.R. Kapadia, E.M. Tuzcu, S.E. Nissen, and R. Puri 2551

Editorial

Variability in atherogenic lipoproteins and coronary artery disease progression
F. Alfonso, F. Rivero, and F. Sánchez-Madrid

2559

BASIC SCIENCE

Coronary artery disease

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths

M. Ruuth, S.D. Nguyen, T. Vihervaara, M. Hilvo, T.D. Laajala, P.K. Kondadi, A. Gisterå, H. Lähteenmäki, T. Kittilä, J. Huusko, M. Uusitupa, U. Schwab, M.J. Savolainen, J. Sinisalo, M.-L. Lokki, M.S. Nieminen, A. Jula, M. Perola, S. Ylä-Herttula, L. Rudel, A. Öörni, M. Baumann, A. Baruch, R. Laaksonen, D.F.J. Ketelhuth, T. Aittokallio, M. Jauhiainen, R. Käkälä, J. Borén, K.J. Williams, P.T. Kovanen, and K. Öörni

2562

Editorial

Pathological phenotypes of LDL particles
U. Laufs and O. Weingärtner

2574

CLINICAL RESEARCH

Lipids

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

G.F. Watts, D.C. Chan, R. Somaratne, S.M. Wasserman, R. Scott, S.M. Marcovina, and P.H.R. Barrett


2577

Editorial

PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
A. Pirillo and A.L. Catapano

2586

Prevention and epidemiology



Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting

R. Verbeek, R.M. Hoogeveen, A. Langsted, L.C.A. Stiekema, S.L. Verweij, G.K. Hovingh, N.J. Wareham, K.-T. Khaw, S.M. Boekholdt, B.G. Nordestgaard, and E.S.G. Stroes

2589

Editorial

Lipoprotein(a): the perpetual supporting actor
B. Gencer and F. Mach

2597

DISCUSSION FORUM

New prospects for PCSK9 inhibition?

U. Landmesser, M.J. Chapman, J.K. Stock, P. Amarenco, J.J.F. Belch, J. Borén, M. Farnier, B.A. Ference, S. Gielen, I. Graham, D.E. Grobbee, G.K. Hovingh, T.F. Lüscher, M.F. Piepoli, K.K. Ray, E.S. Stroes, O. Wiklund, S. Windecker, J.L. Zamorano, F. Pinto, L. Tokgözoğlu, J.J. Bax, and A.L. Catapano; European Society of Cardiology/European Atherosclerosis Society Task Force

2600

Are the proprotein convertase subtilisin/kexin type 9 inhibitors new therapeutic chance for patients with familial hypercholesterolaemia and liver failure?

R. Glowczynska, A. Hus, J. Raszeja-Wyszomirska, and G. Opolski

2602

CARDIOVASCULAR FLASHLIGHTS

Cardiac manifestation of polyarteritis nodosa

B. Peters, J. von Spiczak, F. Ruschitzka, O. Distler, R. Manka, and H. Alkadhi

2603

Superior and inferior vena cava obstruction: an unusual presentation of a rare primary cardiac tumour

P. Kogoj, R. Zbačnik, Z. Dolenc-Stražar, T. Klokočovnik, and M. Cvijić

2604



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org